FDA Says Diabetes Drugs Onglyza, Nesina May Increase Heart Failure Risk
The active pharmaceutical ingredient in the drugs are saxagliptin and alogliptin, the FDA said. Saxagliptin is in Onglyza and Kombiglyze, the second of which is a combination drug with metformin, another diabetes drug.
Alogliptin is in Nesina, Kazano (a combination with metformin) and Oseni (a combination with pioglitazone).
New Warnings Added...
To view the full article, register now.